Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization

Related Keywords

Boston ,Massachusetts ,United States ,Matt Pera ,Inozyme Pharma ,Stefan Riley ,Company Or Inozyme ,Corporate Communications ,Twitter ,Nasdaq ,Inozyme Pharma Inc ,Facebook ,Stock Incentive Plan ,Nasdaq Listing Rule ,Senior Director ,